Radiation dosimetry of [⁶⁸Ga]PSMA-11 in low-risk prostate cancer patients.

ABSTRACT:

Background

⁶⁸Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC ([⁶⁸Ga]PSMA-11) has been increasingly used to image prostate cancer using positron emission tomography (PET)/computed tomography (CT) both during diagnosis and treatment planning. It has been shown to be of clinical value for patients both in the primary and secondary stages of prostate cancer. The aim of this study was to determine the effective dose and organ doses from injection of [⁶⁸Ga]PSMA-11 in a cohort of low-risk prostate cancer patients.

Methods

Six low-risk prostate cancer patients were injected with 133-178 MBq [⁶⁸Ga]PSMA-11 and examined with four PET/CT acquisitions from injection to 255 min post-injection. Urine was collected up to 4 h post-injection, and venous bl

SUBMITTER: Sandgren K 

PROVIDER: S-EPMC6328430 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature